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Vaccine Children (n ¼ 18) Adults (n ¼ 45)
Tetanus 77% 63%
Diphtheria 79% 74%
Pertussis 92% 61%
Haemophilus inﬂ. B 88% 91%
Polio 85% 76%
Pneumococcus 60% 46%
Table 1
Timing of PCP infection after HSCT and differences among cases vs. controls
Factor <60 days 60-270 days >270 days
Proportion of PCP cases 26% 51% 24%
Bactrim prophylaxis* 36% vs. 35% 14% vs. 43% 11% vs. 21%
Grade 3-4 aGVHD* 29% vs. 17% 31% vs. 24% 42% vs. 21%
cGVHD* 79% vs. 44%
*Cases vs. controls; performed on nested case control analysis from data
collected on secondary forms of allo HSCT (n¼ 117).
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transplanted for hematologic malignancies with CNI/MMF
prophylaxis between 10/2005-2/2012. Vaccination criteria
were 1 year post-CBT (earlier in select children), CD4+
>200 cells/ul, & independence from IVIg.
Results: Of 132 patients transplanted, 41 died or relapsed
prior to 1-year. Of 91 remaining patients, 67 (74%) were
vaccinated of whom 63 were evaluable with titer responses.
GVHD was the most common reason for survivors not to be
vaccinated (18/91, 20%). Median age of 63 evaluable vaccine
recipients was 34 years (range 0.9-64); the median time to
vaccination was +17 months (range 7-45). Vaccination was
delayed in 39 CBTs with prior gr. II-IV acute &/or mod-severe
chronic GVHD (+17 months, range 9-45) compared to no
signiﬁcant prior GVHD (+14 months, range 7-33), & in 13
Rituximab (+19 months, range 12-45) recipients. Responses
to the primary series vaccines in children < 18 years & adults
are shown (Table). Responses were seen even in the setting
of prior GVHD or prior Rituximab. Immune function prior to
vaccination did not inﬂuence responses to pneumococcus, H.
inﬂuenza, pertussis or diphtheria vaccines. However, those
with recovery > median CD4+CD45RA+ (>127/ul) & CD19+
(> 793/ul) counts had increased likelihood of tetanus (p ¼
.09 & p ¼ .04) & polio (p ¼ .05 & p ¼ .02) responses. There
were no serious vaccine reactions & with a median 54 month
(range 22-96) follow-up of vaccinated patients, their survival
is 100%.
Conclusions: CBT recipients, including adults & those with
prior GVHD, are capable of responding to tetanus, diphtheria,
pertussis, H. Inﬂuenza, polio & pneumococcal conjugate
vaccines similar to reported adult donor allograft series.
Furthermore, our data suggests improved immune recovery
(CD4+45RA+ & CD19+ subsets) prior to vaccination can
augment vaccine efﬁcacy. However, GVHD can hinder the
ability to commence vaccines in long-term survivors. Addi-
tionally, the sub-optimal responses to non-live vaccines in
some recipients highlight the need to obtain pre- & post-
vaccine titers to document responses, investigate the optimal
timing & number of vaccines, & the role of boosters & CD27+
memory B-cell measurement to predict response.
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Pneumocystis jiroveci pneumonia (formerly PCP) is associ-
ated with high morbidity and mortality after HSCT. Little is
known about PCP infections after HSCT due to presumed
rarity of disease after the advent of prophylaxis. We report
results of a CIBMTR study evaluating the incidence, timing,
prophylaxis agents, risk factors, and mortality of PCP in
autologous (auto) and allogeneic (allo) HSCT recipients. For
recipients of ﬁrst HSCT captured between 1995 and 2005,
PCP infection was documented in 0.63% (n¼177) of allo
(n¼27,934) and 0.28% (n¼52) of auto (n¼18525) HSCT. After
allo-HSCT, cases were distributed early and late after HSCT
(Table 1). A nested case control study was performed con-
trolling for auto vs. allo, primary disease, and alive at PCP
diagnosis, to evaluate risk factors for PCP, the inﬂuence of
PCP prophylaxis agents on the risk of PCP, and the effect of
PCP on overall survival using supplemental data (n¼68 allo
cases, n¼111 allo controls). In univariate analysis, PCP
infection was higher among recipients who were not
Caucasian (p¼.001), received PB (vs. BM) (p¼.027), campath/
ATG (p ¼ .02), less well-matched grafts (p ¼ <.001), and had
lymphopenia (p<.001) or steroids (p <.001) in the 30 days
prior to PCP. Other risk factors are described by onset time of
PCP after HSCT (Table 1). Prophylaxis agents varied but the
use of Bactrim was lower in cases occurring late. There were
more cases with grade 3-4 acute GVHD and chronic GVHD vs.
controls. After allo HSCT, overall survival (OS) was signiﬁ-
cantly poorer among cases vs. controls [1 year: 41% vs. 73%
(p<.0001); 5 year: 25% vs. 56% (p<.0001)]. Similarly,
following auto HSCT, OS was lower in cases vs. controls
(1year: 42% vs. 86% (p¼.0004); 5 year: 13% vs. 52%
(p¼.0003)). After controlling for signiﬁcant variables (age,
disease status, GVHD prophylaxis, year of HSCT, aGVHD),
proportional hazards model revealed that PCP cases were
6.87x more likely to die vs. matched controls (p<.0001, CI
4.84-9.75). Thus, these data reveal that: PCP infection is rare
after HSCT; PCP occurs both early and late after HSCT;
mismatch, GVHD prophylaxis, and GVHD and steroids are
risk factors for PCP; and PCP infection is associated with
higher mortality rate after allo and auto HSCT. Furthermore,
our data suggest opportunities to improve supportive care,
starting PCP prophylaxis early post-HSCT and continuing for
those with these newly identiﬁed risk factors: GVHD, steroid
exposure, or poor immune reconstitution.CRA -DATA MANAGEMENT109
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